INDUSTRY SESSIONS

​​​

Saturday, October 29, 2016

13:00 – 14:30

AUD I

FRONT-LINE OVARIAN CANCER: CAN WE DO BETTER? TODAY, TOMORROW

Symposium Organized by: ROCHE

Chair: Sandro Pignata  (Italy)

13:00     DOING IT BETTER FROM THE BEGINNING

Sandro Pignata  (Italy)

13:10     NEOADJUVANT TODAY AND TOMORROW: EXPERTS EXPERIENCE SHARING

Roman Rouzier (France)

13:25     DEBATE AT THE OPERATING TABLE

Sven Mahner (Germany) and Antonio Gonzalez Martin (Spain)

13:45    ADJUVANT THERAPY TODAY – WHAT'S NEW?

Nicoletta Colombo (Italy)

14:05    ADJUVANT THERAPY TOMORROW – WHAT'S NEXT?

Angeles Secord (USA)

​14:25   WE CAN DO BETTER – TODAY AND TOMORROW

Sandro Pignata  (Italy)


18:15 – 19:45

AUD I

THE ROLE OF IMMUNE CHECKPOINT INHIBITORS IN OVARIAN CANCER

Symposium Organized by: Merck-Pfizer 

Chair: Jonathan Ledermann (United Kingdom)

18:15     WELCOME AND INTRODUCTION

Jonathan Ledermann  (United Kingdom)

18:25     PRECLINICAL RATIONALE

Stéphanie Gaillard (USA)​

18:45     CLINICAL DATA

Eric Pujade-Lauraine (France)

19:15    ONGOING TRIALS AND KEY CONSIDERATIONS FOR CLINICAL TRIAL DESIGN

Brad Monk (USA)

19:35​    Q&A / CLOSING COMMENTS

Jonathan Ledermann  (United Kingdom)


18:15 – 19:45

AUD VI + VII

TREATING OVARIAN CANCER: RIGHT PATIENT. RIGHT TREATMENT. RIGHT TIME.

Symposium Organized by: Astrazeneca

Chair: Nicoletta Colombo (Italy)

18:15     WELCOME AND INTRODUCTION

Nicoletta Colombo  (Italy)

18:20     TREATING RELAPSED OVARIAN CANCER

Nicoletta Colombo (Italy)

18:40     TRANSLATING CLINICAL TRIALS INTO CLINICAL PRACTICE

Mansoor Mirza (Denmark)

19:00    IDENTIFYING SUITABLE PATIENTS FOR PARP INHIBITOR THERAPY IN OVARIAN CANCER: TODAY AND THE FUTURE

Susana Banerjee (UK)

19:20   PANEL/AUDIENCE Q&A

19:40  SUMMARY AND CLOSE



Sunday, October 30, 2016

13:00 – 14:00

3B

MEET THE ROBOTIC PROFESSORS

Symposium Organized by: Intuitive Surgical

13:00     FROM OPEN TO ROBOTOC SURGERY

Angelo Maggioni, Italy

13:30     FROM LAPAROSCOPIC TO ROBOTIC SURGERY

Fabrice Lecuru, France​


13:30 – 15:00

AUD I

MANAGING RELAPSED OVARIAN CANCER IN A RAPIDLY EVOLVING LANDSCAPE

Symposium Organized by: Pharmarmar 

Chair: Andrés Poveda,Spain and Christian Marth (Austria)

13:30     WELCOME AND INTRODUCTION (CHRISTIAN MARTH)

Christian Marth, Austria  

13:35     UPDATE ON RELAPSED OVARIAN CANCER TREATMENT, FROM NEW CONSENSUS TO  DAILY CLINICAL PRACTICE

Antonio González, Spain

13:5​5     DEBATE: PLATINUM OR NON-PLATINUM, THAT IS THE QUESTION

Moderated by: Andrés Poveda,Spain and Christian Marth, Austria  

14:15     TRABECTEDIN MOA AND PLATINUM RESISTANCE: MOLECULAR RATIONALE

Isabelle Ray-Coquard, France

14:30     WHEN NON-PLATINUM IS THE ANSWER: THE ROLE OF TRABECTEDIN+PLD

Nicoletta Colombo, Italy

​14:50     QUESTIONS AND CLOSING

Andrés Poveda,Spain​


Monday October 31st, 2016

​8:00 – 9:00​

AUD III + IV

HE4 BIOMARKER ADOPTION: CURRENT AND FUTURE APPLICATIONS

Symposium Organized by: Fujirebio Diagnostics​

Chair: Christianne Lok (The Netherlands)

08:00  ADDED VALUE OF HE4 SERUM MARKER IN OVARIAN CANCER PATIENTS

Sharon O'Toole AND Noreen Gleeson (Ireland)

08:30 IMPROVING TRIAGE AND CARE IN GYNECOLOGICAL CANCER (ENDOMETRIAL AND OVARIAN): ROLE OF  HE4 BIOMARKER

Christianne Lok (The Netherlands)


 



Keep Me Updated